Cancer Treatment Reviews
Volume 24, Issue 2 , Pages 101-111 , April 1998

Clinical, pathological and therapeutic aspects of oligodendroglioma

References 

  1. Mork SJ, Lindegaard KF, Halvorsen TB. Oligodendroglioma: incidence and biological behaviour in a defined population. J Neurosurg. 1985;63:881–889
  2. Fleury A, Menegoz F, Grosclaude P. Descriptive epidemiology of cerebral gliomas in France. Cancer. 1997;79:1195–1202
  3. Bishop M, De la Monte SM. Dual lineage of astrocytomas. Am J Pathol. 1989;135:517–527
  4. De la Monte SM. Uniform lineage of oligodendrogliomas. Am J Pathol. 1989;135:529–540
  5. Linskey ME, Gilbert MR. Glial differentiation: a review with implications for new directions in neuro-oncology. Neurosurgery. 1995;36:1–22
  6. Parker RJ, Sutton LN, Rorke LB. Oligodendroglioma of the posterior fossa in childhood. Cancer. 1985;56:195–199
  7. Ludwig CL, Smith MT, Godfrey AD. A clinicopathological study of 323 patients with oligodendrogliomas. Ann Neurol. 1986;19:15–21
  8. Chin HW, Hazel JJ, Kim TH, et al.  Oligodendrogliomas. In: A clinical study of cerebral oligodendrogliomas. 4th edition. Cancer. 45:1980;p. 1458–1499
  9. Nijjar TS, Simpson WJ, Gadalla T, et al.  Oligodendroglioma. In: The Princess Margaret Hospital experience. 4th edition. Cancer. 71:1993;p. 4006–4402
  10. Reedy DP, Bay JW, Hahn JF. Role of radiation therapy in the treatment of cerebral oligodendroglioma: an analysis of 57 cases and a literature review. Neurosurgery. 1983;13:499–503
  11. Shaw EG, Scheithauer WS, O'Fallon JR, et al.  Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg. 1992;76:428–434
  12. Shuman WP, Griggin BR. The utility of MR in planning the radiation therapy of oligodendroglioma. Am J Roentgenol. 1987;148:595–600
  13. Derlon JM, Petit-Taboue MC, Chapon F. The in vivo metabolic pattern of low grade brain gliomas: a positron emission tomographic study using 18-F-fluorodeoxyglucose and 11C-l-methylmethionine. Neurosurgery. 1997;40:276–287
  14. Kernohan JW, Mabon RF, Svien HJ. A simplified classification of the gliomas. In: 4th edition. Proc Staff Meet Mayo Clin. 24:1949;p. 71–75
  15. Smith MT, Ludwig CL, Godfrey AD, et al.  Grading of oligodendroglioma. Cancer. 1983;52:2107–2114
  16. Burger PC, Rawlings CE, Cox EB. Clinicopathologic correlations in the oligodendroglioma. Cancer. 1987;59:1345–1352
  17. Kros JM, Troost D, Van Eden G. Oligodendroglioma. In: A comparison of two grading systems. 4th edition. Cancer. 61:1988;p. 2251–2259
  18. Burger PC, Scheithauer BW. Central Nervous System, Atlas of Tumor Pathology. 3rd series In: Washington, DC: Armed Forces Institute of Pathology; 1994;p. 107–120
  19. Lindegaard KF, Mork SJ, Eide GE, et al.  Statistical analysis of clinicopathological feature, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg. 1987;67:224–230
  20. Mork SJ, Halvorsen TB, Lindegaard KF. Oligodendroglioma: histological evaluation and prognosis. J Neuropathol Exp Neurol. 1986;45:65–78
  21. Daumas-Duport C, Tucker ML, Kolles H. Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neuro-Oncol. 1997;34:61–78
  22. Shaw EG, Scheithauer BW, O'Fallon JR. Supratentorial gliomas: a comparative study by grade and histologic type. J Neuro-Oncol. 1997;31:273–278
  23. Wallner KE, Gonzales M, Sheline GE. The treatment of oligodendrogliomas with or without postoperative irradiation. Cancer. 1988;68:684–688
  24. Shaw EG. In search of better prognostic indicators for patients with oligodendrogliomas. Cancer Invest. 1996;14(3):288–289
  25. Heegard S, Sommer HM, Broholm H. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer. 1995;76:1809–1813
  26. Kros JM, Van Eden CG, Vissers CJ. Prognostic relevance of DNA flow cytometry in oligodendroglioma. Cancer. 1992;69:1791–1798
  27. Kros JM, Hop WC, Godschalk JJ. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer. 1996;78:1107–1113
  28. Ganju V, Jenkins RB, O'Fallon JR. Prognostic factors in gliomas: a multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic and molecular markers. Cancer. 1994;74:920–927
  29. Celli P, Nofrone I, Palma L, et al.  Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery. 1994;35:1018–1034
  30. Peterson K, Cairncross JG. Oligodendroglioma. Cancer Invest. 1996;14:243–251
  31. Kros JM, Pieterman H, Van Eden CG, et al.  Oligodendroglioma: the Rotterdam-Dijkzigt experience. Neurosurgery. 1994;34:959–966
  32. Sun ZM, Genka S, Shitara N, et al.  Factors possibly influencing the prognosis of oligodendroglioma. Neurosurgery. 1988;22:886–891
  33. Chen R, Macdonald DR, Ramsay DA. Primary diffuse leptomeningeal oligodendroglioma. In: Case report. 4th edition. J Neurosurg. 83:1995;p. 724–728
  34. Macdonald DR, O'Brien RA, Gilbert JJ. Metastatic anaplastic oligodendroglioma. Neurology. 1989;39:1593–1596
  35. Schuster H, Jellinger K, Gund A, Regele H. Extracranial metastases of anaplastic cerebral gliomas. Acta Neurochir (Wien). 1976;35(4):247–259
  36. Roelvink NC, Kamphorst W, Lindhout D. Concordant cerebral oligodendroglioma in identical twins. J Neurol Neurosurg Psychiatry. 1986;49:706–708
  37. Shaw EG, Scheithauer BW, O'Fallon JR, et al.  Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery. 1994;34:577–582
  38. Whitton AC, Bloom HJ. Low grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. Int J Radiat Oncol Biol Phys. 1990;18:783–786
  39. Bullard DE, Rawlings CE, Halperin E. Oligodendroglioma, an analysis of the value of radiation therapy. Cancer. 1987;60:2179–2188
  40. Gannett DE, Wisbeck WM, Silbegerd DL. The role of post-operative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys. 1994;30:567–573
  41. Shimizu KT, Tran LM, Mark RJ, et al.  Management of oligodendrogliomas. Radiology. 1993;186:569–572
  42. Glass J, Hochberg FH, Gruber ML, et al.  The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg. 1992;76:741–745
  43. Levin VA, Edwards MS, Wright DC, et al.  Modified procarbazine, CCNU and vincristine (PCV-3) combination chemotherapy in the treatment of malignant brain tumor. Cancer Treat Rep. 1988;64:237–241
  44. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 1988;23:360–364
  45. Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery. 1992;31:78–82
  46. Kyritsis AP, Yung WKA, Bruner J, et al.  The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery. 1993;32:365–371
  47. Cairncross G, Macdonald D, Ludwin S, et al.  Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol. 1994;12:2013–2021
  48. Soffietti R, Chiò A, Mocellini C. Response of oligodendroglial tumors to PCV chemotherapy. Neurology. 1994;44:309
  49. Glass J, Hochberg FH, Gruber ML. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytoma with PCV chemotherapy. J Neurosurg. 1992;76:741–745
  50. Van Den Bent MJ, Kros JM, Schellens JHM. PCV-chemotherapy in anaplastic oligodendroglioma: time for a prospective, randomized study. J Neuro-Oncol. 1996;30:130
  51. Salgado D, Costa I, Pimentel T. PCV for anaplastic oligodendroglioma. J Neuro-Oncol. 1996;30:224
  52. Soffietti R, Rudà R, Borgognone M. Role of chemotherapy in oligodendroglial tumors: a review of the experience at the University of Toronto. J Neuro-Oncol. 1996;30:153
  53. Duffau H, Albuquerque L, Ameri A. Chemotherapy for newly diagnosed and recurrent anaplastic oligodendrogliomas and mixed gliomas: an analysis of 42 cases. Neurology. 1995;45:261
  54. Paleologos N, MacDonald D, Vick N. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic oligodendroglioma and aggressive oligodendroglioma. Neurology. 1995;45:387
  55. Brown M, Caincross JG, Vick NA. Differential response of recurrent oligodendrogliomas versus astrocytomas to intravenous melphalan. Neurology. 1990;40:387
  56. Soffietti R, Chiò A, Mocellini C. Treatment with carboplatinum of oligodendroglial tumors recurrent after PCV chemotherapy. Neurology. 1995;45:261
  57. Peterson K, Paleologos N, Forsyth P. Salvage chemotherapy for oligodendroglioma. J Neurosci. 1996;85:597–601
  58. Saarinen UM, Pihko H, Makipernaa A. High-dose thiotepa with autologus bone marrow rescue in recurrent malignant oligodendroglioma: a case report. J Neuro-Oncol. 1990;9:57–61
  59. Mason WP, Krol GS, DeAngelis LM. Low grade oligodendroglioma responds to chemotherapy. Neurology. 1996;46:203–207
  60. Paleologos NA, Nicholas AV, Kachori-Evaston JP. Chemotherapy for low grade oligodendrogliomas?. Ann Neurol. 1994;36:294–295
  61. Duffey P, Chari G, Cartlidge N. Progressive deterioration of intellect and motor function occurring several decades after cranial irradiation. Arch Neurol. 1996;53:814–818
  62. Imperato JP, Paleologos N, Vick N. Effects of treatment on long term survivors with malignant astrocytomas. Ann Neurol. 1990;28:818–822

PII: S0305-7372(98)90076-7

Cancer Treatment Reviews
Volume 24, Issue 2 , Pages 101-111 , April 1998

Article Tools